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The Role of the Eukaryotic
Translation Initiation Factor 4E
(eIF4E) in Neuropsychiatric Disorders
Inês S. Amorim1, Gilliard Lach1 and Christos G. Gkogkas1,2*
1 Centre for Discovery Brain Sciences, The University of Edinburgh, Edinburgh, United Kingdom, 2 The Patrick Wild Centre,
The University of Edinburgh, Edinburgh, United Kingdom
Protein synthesis in eukaryotic cells is a complex, multi-step and tightly regulated
process. Translation initiation, the rate limiting step in protein synthesis, is dependent
on the activity of eukaryotic translation Initiation Factor 4E (eIF4E). eIF4E is the cap-
binding protein which, in synergy with proteins such as the helicase eIF4A and the
scaffolding protein eIF4G, binds to mRNA, allowing the recruitment of ribosomes and
translation initiation. The function of eIF4E is tightly regulated in cells under normal
physiological conditions and can be controlled by post-translational modifications, such
as phosphorylation, and by the binding of inhibitory proteins, including eIF4E binding
proteins (4E-BPs) and CYFIP1. Recent studies have highlighted the importance of eIF4E
in normal or aberrant function of the nervous system. In this mini-review, we will highlight
the role of eIF4E function and regulation in the pathophysiology of neurodevelopmental
and neuropsychiatric disorders.
Keywords: eIF4E, neurodevelopmental/neuropsychiatric disorders, anxiety, depression, protein synthesis,
translation, Autism Spectrum Disorders, Fragile X Syndrome
INTRODUCTION
In Archaea and Bacteria, the mRNA Shine-Dalgarno sequence promotes binding of the ribosome
to mRNA and thus translation initiates (Shine and Dalgarno, 1975). Contrary to that, the
majority of eukaryotic precursor mRNAs harbor a 5′ end cap, a 7 methylguanosine triphosphate
(m7GpppG) structure, which serves as a docking point for eukaryotic translation initiation
factors (eIFs) (Furuichi and Miura, 1975; Shatkin, 1976; Furuichi et al., 1977; Sonenberg et al.,
1979). eIF4E directly binds the mRNA 5′ cap (Sonenberg et al., 1979) and interacts with
the scaffolding protein eIF4G, which in turn binds the helicase eIF4A to form the eIF4F
complex and allow the recruitment of ribosomes to initiate the predominant form of eukaryotic
translation: cap-dependent translation (Gingras et al., 1999). eIF4G provides the backbone of
the eIF4F complex. In addition, it helps to circularize mRNAs through its interaction with
poly(A) binding proteins (PABPs) and provides a binding site for other regulatory factors,
such as MAP kinase-interacting serine/threonine-protein kinases 1/2 (MNK1/2) and eukaryotic
Initiation Factor 3 (eIF3). The eIF4A helicase unwinds secondary structures present in the
mRNA 5′ Untranslated Regions (UTRs) to facilitate translation. eIF4A helicase activity is
promoted by eIF4G and eIF4B (Gingras et al., 1999), as well as eIF4E (Feoktistova et al., 2013).
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Cap-dependent translation is responsible for the bulk of protein
synthesis in eukaryotic cells, and is the rate limiting step in
protein synthesis. Crucially, eIF4E and the eIF4F complex carry a
well-conserved function in eukaryotes, where they preferentially
regulate the synthesis of a subset of proteins, by controlling
mRNA translation initiation (Pelletier and Sonenberg, 1987;
Sonenberg and Hinnebusch, 2007, 2009; Hinnebusch et al., 2016).
Thus, the term “eIF4E/eIF4F-sensitive” mRNAs has emerged
(Hinnebusch et al., 2016). Consequently, eIF4E activity is tightly
regulated by a variety of factors such as hormones, growth
factors, cytokines and other extracellular stimuli, which converge
on two major signaling cascades: MAPK/ERK and PI3K/mTOR
pathways (Joshi and Platanias, 2014; Saxton and Sabatini, 2017;
Figure 1).
The PI3K/mTOR pathway regulates eIF4E function via the
action of eIF4E-binding proteins (4E-BPs) (Pause et al., 1994).
4E-BPs compete with eIF4G for binding on the dorsal surface
of eIF4E, hence disrupting the formation of the eIF4F complex
(Pause et al., 1994). Hypo-phosphorylated 4E-BPs have a higher
affinity for eIF4E and thus repress translation initiation (Gingras
et al., 2001). Conversely, activation of PI3K/mTOR signaling
FIGURE 1 | The role of eIF4E in translational control. Diagram of the major
signaling pathways upstream of eIF4E. 4E-BPs, eIF4E-binding proteins; Akt,
also known as Protein kinase B (PKB); eIF3, eukaryotic initiation factor 3;
eIF4A, eukaryotic translation initiation factor 4A; eIF4E, eukaryotic translation
initiation factor 4E; eIF4G, eukaryotic translation initiation factor 4G; ERK,
extracellular signal–regulated kinase, also known as mitogen-activated protein
kinase (MAPK); GβL, G protein beta subunit-like; MEK: mitogen-activated
protein kinase kinase; MNK1/2, mitogen-activated protein (MAP)
kinase-interacting serine/threonine-protein kinases 1/2; mTOR, mechanistic
target of rapamycin; mTORC1, mechanistic target of rapamycin complex 1;
off, repression of translation; on, active translation; P, phosphorylation site;
PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin homolog;
RAPTOR, regulatory-associated protein of mTOR; TSC1/2, Tuberous sclerosis
proteins 1/2.
leading to downstream phosphorylation of 4E-BPs by mTORC1,
triggers the release of 4E-BPs from eIF4E. As a result, the
availability of eIF4E for initiation increases (Haghighat et al.,
1995; Richter and Sonenberg, 2005).
Activation of MAPK/ERK pathway leads to phosphorylation
of eIF4E at the Serine 209 residue by MNK1/2 (Joshi et al.,
1995; Ueda et al., 2004). MNK1/2 are recruited to the eIF4F
complex by binding to the c-terminal domain of eIF4G,
where they promote the phosphorylation of eIF4E (Pyronnet
et al., 1999; Shveygert et al., 2010). While two studies
suggested that eIF4E phosphorylation is either not required
for translation (McKendrick et al., 2001) or that it decreases
cap-dependent translation (Knauf et al., 2001), the majority
of the literature suggests that eIF4E phosphorylation promotes
initiation (Pyronnet et al., 1999; Lachance et al., 2002; Panja
et al., 2014; Bramham et al., 2016). Moreover, several studies
have identified phospho-eIF4E-sensitive mRNAs in cancer (Furic
et al., 2010; Grzmil et al., 2011; Konicek et al., 2011; Robichaud
et al., 2015) and in the nervous system (Gkogkas et al., 2014;
Cao et al., 2015; Amorim et al., 2018). eIF4F complex formation
is also affected by sequestering eIF4E in a repressive complex
with the Fragile X Mental Retardation Protein (FMRP) and the
Cytoplasmic FMRP Interacting Protein (CYFIP1) (Napoli et al.,
2008). The eIF4E-CYFIP complex is sensitive to MNK1/2 activity
and precludes eIF4E-eIF4G binding, thus hindering translation
initiation (Napoli et al., 2008; Panja et al., 2014; Genheden et al.,
2015; Bramham et al., 2016).
eIF4E-dependent translational control is linked to several
cellular processes, including cell cycle progression, cell survival,
cell motility and tumorigenesis (Rhoads et al., 1993; Malka-
Mahieu et al., 2017; Steinberger et al., 2017), as well as
inflammation, immunity and viral infection (Jan et al., 2016;
Hoang et al., 2018). Nevertheless, a growing body of evidence
indicates eIF4E-dependent translation is important for neuronal
cell function and implicates its aberrant function in nervous
system disorders (Figure 2), such as neurodevelopmental and
neuropsychiatric conditions (Costa-Mattioli and Monteggia,
2013; Santini and Klann, 2014; St Clair and Johnstone, 2018).
AUTISM SPECTRUM DISORDERS (ASD)
AND FRAGILE X SYNDROME (FXS)
Autism Spectrum Disorders are a group of heterogeneous
neurodevelopmental conditions characterized by persistent
deficits in sociability, impaired communication, and the presence
of restricted or repetitive stereotypical behaviors (Elsabbagh et al.,
2012). ASDs are amongst the most common neurodevelopmental
disorders, with an estimated prevalence of 16:1000 in children
aged 8 years in the United States and high heritability (Sandin
et al., 2017; Baio et al., 2018). ASDs have been linked to a variety
of genetic mutations and risk factors, including genetic variants
in conditions such as Rett syndrome, Tuberous Sclerosis and
FXS (Carter and Scherer, 2013). FXS is one of the most common
inherited forms of intellectual disability and is the leading genetic
cause of ASDs (Gabis et al., 2011; McCary and Roberts, 2013).
FXS is caused by a mutation (CGG nucleotide repeats) in the 5′
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FIGURE 2 | eIF4E in neurodevelopmental and neuropsychiatric disorders. Diagram of the control of eIF4E function by ERK and mTOR signaling pathways,
highlighting the new roles of eIF4E in depression, maternal immune activation (MIA), repeat-associated non-AUG (RAN) translation and in early development. Top left:
Decreased phosphorylation of eIF4E promotes depressive and anxiety behaviors by relieving translational repression of pro-inflammatory mRNAs containing
repressive 3′ GAIT elements of translation; Bottom left: eIF4E and mTOR are dysregulated in gene expression profiles following MIA, a risk factor for the development
ASD; Top right: RAN translation, a process important for the synthesis of toxic polypeptides containing poly nucleotide repeats, such as FMRP, requires functional
eIF4E; Bottom right: eIF4E interacts with 4E-T in P-bodies, where they sequester and repress the translation of pro-neurogenic mRNAs during early development.
4E-BPs, eIF4E-binding proteins; 4E-T, eIF4E transporter; ASD, Autism Spectrum Disorders; CYFIP1, cytoplasmic FMRP interacting protein; eIF3, eukaryotic initiation
factor 3; eIF4A, eukaryotic translation initiation factor 4A; eIF4E, eukaryotic translation initiation factor 4E; eIF4G, eukaryotic translation initiation factor 4G; ERK,
extracellular signal–regulated kinase, also known as mitogen-activated protein kinase (MAPK); FMRP, Fragile X mental retardation protein; FXS, Fragile X Syndrome;
GAIT complex, interferon (IFN)-γ-activated inhibitor of translation complex; MNK 1/2, mitogen-activated protein (MAP) kinase-interacting serine/threonine-protein
kinases 1/2; MIA, maternal immune activation; mTORC1, mechanistic target of rapamycin complex 1; off, repression of translation; on, active translation; P,
phosphorylation site; PABPs, poly-A binding proteins; PTEN, phosphatase and tensin homolog; RAN, repeat-associated non-AUG; SCZ, Schizophrenia; TSC1/2,
Tuberous sclerosis proteins 1/2.
UTR of the FMR1 gene, leading to transcriptional silencing of
FMR1 and subsequent loss of FMRP expression (Santoro et al.,
2012). FMRP is a translational repressor, thus its loss engenders
an across the board increase in protein synthesis (Li et al., 2001).
Protein synthesis-linked hyperactivation of type I metabotropic
glutamate receptors (mGluRs), leading to synaptic dysfunction,
constitutes the predominant mechanistic theory aiming to explain
the diverse pathophysiology of FXS (Bear, 2005).
Likewise, ASD is believed to arise from common downstream
defects in synaptic function and brain connectivity (Abrahams
and Geschwind, 2008). A leading hypothesis posits that
downstream defects in mRNA translation lead to aberrant local
protein synthesis, which results in altered synaptic development
and plasticity (Kelleher and Bear, 2008; Gkogkas and Sonenberg,
2013). In accordance, patients and animal models of ASD
and FXS show widespread alterations in synaptic plasticity
and dysregulated mRNA translation (Kelleher and Bear, 2008;
Jung et al., 2014; Contractor et al., 2015; Dahlhaus, 2018).
Altered translation in ASD and FXS results not only from
mutations in genes that directly impact on translational control
mechanisms, but also from altered signaling, upstream of
translation (MAPK/ERK and PI3K/mTOR) (Costa-Mattioli and
Monteggia, 2013). A pivotal convergence point of these pathways
is the control of cap-dependent translation, particularly through
the function of the eIF4F complex.
Abnormalities in the EIF4E locus have been identified
in genetic studies of autistic patients (Yonan et al., 2003;
Neves-Pereira et al., 2009; Waltes et al., 2014). Moreover,
a comparison of gene-expression in rodent models of
maternal immune activation (MIA) with ASD patient
cortical gene-expression revealed a strong involvement of
the Tsc2/mTOR/eIF4E axis (Lombardo et al., 2018). MIA
during the first trimester of pregnancy increases the risk
for ASD most likely by affecting fetal brain development.
Notwithstanding some epidemiological evidence, there is
no compelling, direct link of EIF4E to ASDs. Nonetheless,
several reports from animal models of ASD provide strong
evidence for a key role of Eif4e in ASD. Deletion of Eif4ebp2
(the predominant 4E-BP in the brain) or overexpression of
Eif4e in mice lead to altered synaptic excitation/inhibition
balance and altered behaviors, such as social interaction deficits,
altered ultrasonic vocalizations, and repetitive/stereotyped
behaviors (Gkogkas et al., 2013; Santini et al., 2013). Molecular,
electrophysiological and behavioral defects in mice, which are
reminiscent of ASD phenotypes diagnosed in patients, could
be normalized by inhibition of cap-dependent translation
using 4EGI-1 (Gkogkas et al., 2013; Santini et al., 2013), a
small molecule developed as an eIF4E-eIF4G interaction
inhibitor (Moerke et al., 2007). Recent work revealed that type
I mGluR agonists, which were proposed as FXS therapeutics,
also rescue phenotypes reminiscent of ASD in Eif4ebp2
knockout mice (Aguilar-Valles et al., 2015). Furthermore,
4EGI-1 has shown beneficial effects in Fmr1−/y mice, a
model of FXS, where it reversed contextual memory deficits
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and normalized altered dendritic morphology, dysregulated
actin dynamics and exaggerated mGluR-dependent LTD
(Santini et al., 2017). Interestingly, crossing Fmr1−/y
mice with Eif4e overexpressing mice engenders cognitive
impairments in addition to ASD-like phenotypes (Huynh et al.,
2015).
Regulation of eIF4E by phosphorylation is associated with
FXS. Patients and animal models of FXS show increased levels
of phosphorylated eIF4E (Hoeffer et al., 2012; Gkogkas et al.,
2014; Sidhu et al., 2014). Moreover, genetic deletion of the
MNK1/2 kinases, which phosphorylate eIF4E, administration of
the MNK1/2 inhibitor cercosporamide, or substitution of the
eIF4E phosphorylation site for a non-phosphorylatable residue
(Eif4eki/ki mice; Ser209Ala), ameliorated FXS phenotypes in
Fmr1−/y mice (Gkogkas et al., 2014).
In addition to eIF4E phosphorylation, a new translational
control mechanism was found where FMRP interacts with
eIF4E through CYFIP1 to prevent eIF4E-eIF4G binding, thereby
hindering translation initiation (Napoli et al., 2008). The FMRP-
CYFIP1-eIF4E complex is present in dendritic spines and
actively participates in the local control of protein synthesis
during synaptic activity. Synaptic activation by BDNF or mGluR
stimulates the release of FMRP and CYFIP1 from eIF4E and
promotes local translation (Napoli et al., 2008; Genheden et al.,
2015). In fact, the levels of CYFIP1 have been shown to
influence the maturation of dendritic spines (Pathania et al.,
2014; Oguro-Ando et al., 2015), whereas Cyfip1+/− mice show
some phenotypes similar to Fmr1−/y mice, such as exaggerated
mGluR-LTD (Bozdagi et al., 2012).
One avenue through which aberrant eIF4E-dependent
translation may lead to the manifestation of ASDs is through
the translational control of specific subsets of mRNAs. eIF4E
was shown to regulate the translation of mRNAs with 5′ UTRs
that are highly structured (Feoktistova et al., 2013; Hinnebusch
et al., 2016) or that contain CERT (cytosine-enriched regulator
of translation) motifs (Truitt et al., 2015). Furthermore,
phosphorylation of eIF4E has been proposed to affect the
translation of mRNAs containing 3′ GAIT (interferon (IFN)-
γ-activated inhibitor of translation) elements (Amorim et al.,
2018). Subsets of mRNAs controlled by eIF4E perform a variety
of functions, such as promoting tumorigenesis or participating
in the control of the circadian rhythm and serotonin pathways
(Furic et al., 2010; Cao et al., 2015; Amorim et al., 2018). In
addition, eIF4E-sensitive mRNAs encode scaffolding proteins
such as neuroligins (Gkogkas et al., 2013; Pettem et al., 2013;
Rothwell et al., 2014) and extracellular matrix components
(Gkogkas et al., 2014; Amorim et al., 2018). Mutations in
several neuroligin isoforms are present in ASD patients (Jamain
et al., 2003). In addition, overproduction of neuroligins was
shown to modulate synaptic function and behavior in animal
models of ASD and FXS (Hines et al., 2008; Dahlhaus and
El-Husseini, 2010; Dahlhaus et al., 2010; Gkogkas et al., 2013).
Extracellular matrix metalloproteinase 9 (MMP-9) regulates
spine morphology, synaptic plasticity, learning and memory
(Huntley, 2012), and is implicated in phenotypes in rodent
models of ASD and FXS (Bilousova et al., 2009; Rotschafer
et al., 2012; Dziembowska et al., 2013; Sidhu et al., 2014).
Translation of MMP-9 is stimulated by eIF4E phosphorylation,
the levels of which are increased in FXS patients and Fmr1−/y
mice (Hoeffer et al., 2012; Gkogkas et al., 2014; Sidhu et al.,
2014). In addition, modulation of MMP-9 expression in
rodents modulates FXS phenotypes associated with increased
eIF4E phosphorylation (Gkogkas et al., 2014; Gantois et al.,
2017). Finally, a recent study proposes a novel mechanism,
whereby eIF4E is required for repeat-associated non-AUG
(RAN) translation of the FMR1 gene (Kearse et al., 2016).
CGG repeats in the FMR1 gene stimulate RAN translation,
which leads to the synthesis of toxic polypeptides (Todd et al.,
2013).
Apart from direct translational control, eIF4E may be linked
to ASD pathophysiology via a role in early neuronal development
through its interaction with the eIF4E-Transporter (4E-T) in
processing bodies (P-bodies), which are cytoplasmic granules
involved in mRNA degradation (Eulalio et al., 2007). Here, eIF4E
and 4E-T cooperate to sequester and repress the translation
of pro-neurogenic mRNAs, such as transcription factors and
neuronal differentiation-related mRNAs (Yang et al., 2014). In
addition, recent work revealed that 4E-T also binds to Pumilio2
and that this complex ensures neuronal specification of deep and
superficial layer murine cortical neurons (Zahr et al., 2018).
DEPRESSION AND ANXIETY
DISORDERS
Depressive and anxiety disorders are often comorbid and
represent the most common causes of disability worldwide
(Zhou et al., 2017). In addition, these psychiatric conditions are
commonly present in people suffering from ASDs (Magnuson
and Constantino, 2011). mTOR signaling is affected in patients
with major depressive disorder as well as animal models
of depression and anxiety (Jernigan et al., 2011; Chandran
et al., 2013; Ignacio et al., 2016). Furthermore, treatment with
selective serotonin reuptake inhibitors or other anti-depressant
drugs, such as ketamine, were shown to affect mTOR and its
downstream targets p70S6K and 4E-BP1 (Jernigan et al., 2011;
Park et al., 2014; Liu et al., 2015; Zhuang et al., 2016; Abelaira
et al., 2017). MAPK/ERK signaling is also altered in patients and
animal models of depressive disorders (Dwivedi et al., 2001; Rao
et al., 2007; Dwivedi and Zhang, 2016). Given the convergence
of these two pathways in the control of translation initiation, the
question arises of how eIF4E function may affect or be affected by
depression and anxiety disorders.
Two recent studies revealed that mice with defective eIF4E
phosphorylation (Mnk1/2−/− or Eif4eki/ki mice) show behaviors
reminiscent of depression and anxiety, concomitant with
increased inflammatory responses. Mnk1/2−/− and Eif4eki/ki
mice displayed increased immobility in the force-swimming and
tail suspension tests, increased latency to feed in a novelty
suppressed feeding assay, and anxiety behaviors in the open-field
and elevated plus maze tests (Aguilar-Valles et al., 2018; Amorim
et al., 2018). Translational profiling in brain tissue from Eif4eki/ki
mice revealed increased translation of genes involved in serotonin
pathways concomitantly with reduced levels of serotonin in the
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brain (Amorim et al., 2018). Aguilar-Valles et al. (2018) further
report impaired serotonin transmission in the prefrontal cortex
and reduced firing of serotonergic neurons in the dorsal raphe
of Eif4eki/ki and Mnk1/2−/− mice. Moreover, loss of eIF4E
phosphorylation resulted in elevated levels of key inflammatory
cytokines, including TNFα, IFNγ, and IL-2, in addition to an
exaggerated response to lipopolysaccharide-induced microglial
activation and cytokine production (Aguilar-Valles et al.,
2018; Amorim et al., 2018). Interestingly, administration of a
dominant negative form of TNFα rescued the behavioral and
electrophysiological abnormalities in Eif4eki/ki mice (Aguilar-
Valles et al., 2018).
The connection between depression and inflammation has
received increased attention (Miller and Raison, 2016). There
is an elevated comorbidity between depression and chronic
inflammatory conditions (Abbott et al., 2015; Euesden et al.,
2017), and while several studies have found increased levels
of pro-inflammatory cytokines in patients with anxiety and
major depressive disorder (Dowlati et al., 2010; Shelton et al.,
2011; Mostafavi et al., 2014; Michopoulos et al., 2015), anti-
inflammatory drugs are effective in the treatment of depression
(Müller, 2018; Wiedlocha et al., 2018). The new evidence
from Amorim et al. (2018) suggests an important mechanism
through which impaired translation control via dysregulated
eIF4E phosphorylation downstream of the MAPK/ERK pathway
affects the translation of specific mRNAs to directly influence
the inflammatory response and impact on depression and
anxiety-like behaviors. Amorim et al. (2018) propose that
eIF4E phosphorylation may control inflammatory responses
in depression by regulating binding of the 3′ UTR element
(GAIT) onto the 5′ eIF4F complex in circularized pro-
inflammatory mRNAs. The GAIT complex acts as a translational
repression mechanism that controls the translation of pro-
inflammatory mRNAs (Mukhopadhyay et al., 2009). Loss of
eIF4E phosphorylation may decrease the affinity of the GAIT
complex to eIF4F, thus allowing excessive translation of pro-
inflammatory mRNAs.
SCHIZOPHRENIA (SCZ)
SCZ is a neuropsychiatric disorder characterized by a
combination of positive, negative and cognitive symptoms,
including hallucinations and delusions, apathy and social
withdrawal, and attention, memory and executive thinking
deficits, respectively. SCZ is a highly disabling condition,
affecting around 1% of the population, and it has high heritability
rates (Kahn et al., 2015). The etiology of SCZ is not fully
understood and is associated with a variety of genetic and
environmental risk factors. Even though DISC1 is one of the
better characterized genes regarding its association with SCZ
(Roberts, 2007; Bradshaw and Porteous, 2012), several studies
have additionally identified de novo copy number variants
(CNVs) as conferring high risk for the development of the disease
(Xu et al., 2008; Malhotra et al., 2011). Interestingly, these CNVs
are often associated risk factors for other neurodevelopmental
disorders, such as ASD, mental retardation and epilepsy (Sullivan
et al., 2012). In addition, network analysis has suggested they
affect neurodevelopmental, synaptic function and post-synaptic
signaling pathways (Walsh et al., 2008; Kirov et al., 2012;
Brennand et al., 2015).
One recurrent CNV associated with SCZ, as well as
with cognitive and behavioral abnormalities, is the 15q11.2
microdeletion (Stefansson et al., 2008; Kirov et al., 2009; De
Wolf et al., 2013). The 15q11.2 locus includes four genes –
CYFIP1, TUBGCP5, NIPA1, and NIPA2. Of particular interest is
the CYFIP1 gene, which has emerged as an important player in
ASD and FXS and participates in the control of protein synthesis
and dendritic spine maturation. Furthermore, CYFIP1 is also part
of the WAVE regulatory complex, which is involved in the control
of actin polymerization and lamellipodia formation (Chen et al.,
2010; Abekhoukh et al., 2017). The functioning of this complex
and of CYFIP1 contribute to the correct formation of adherens
junctions and cell polarity in patient-derived induced pluripotent
stem cells (iPSCs) neuroprogenitor cells (Yoon et al., 2014).
Other studies have used iPSCs-derived neuronal populations to
address SCZ-related impairments in cell migration, cytoskeletal
remodeling and protein synthesis (Brennand et al., 2015; Topol
et al., 2015). Interestingly, by using olfactory neurosphere-
derived cells, a model that was shown to replicate some of the
molecular phenotypes of SCZ (Mackay-Sim, 2012), English et al.
(2015) identified, both at the level of the transcriptome and
proteome, significant changes in signaling pathways key to the
control of mRNA translation, including eIF2, eIF4 and mTOR
signaling. Although the role of mTOR in SCZ has not been well
established, various studies have noted the presence of altered
mTOR signaling, particularly in the context of DISC1 animal
models (Kim et al., 2009; Zhou et al., 2013; Gururajan and van den
Buuse, 2014). Exploring the relationship between mTOR and SCZ
will be particularly interesting in terms of its connection to eIF4E,
given the ability of this initiation factor to interact with CYFIP1
and to influence crucial mechanisms to SCZ, such as dendritic
spine morphology and neurodevelopment.
CONCLUSION – OUTLOOK
The genomic and gene-expression “boom” of the early
00’s, bolstered by the advent of technologies to measure
transcriptional changes (micro-array, RNA/exome/whole
genome next generation sequencing) has placed a focus on
transcription as the key step in the gene-expression pathway
underlying the pathophysiology of neuropsychiatric disorders
(Kelsoe, 2004; Kavanagh et al., 2013; Nievergelt et al., 2018).
Thus, the regulatory mechanisms of protein synthesis have
not received much attention, while translational control and
investigation of the translatome has not become part of large
consortia mainly due to the lack of accessible genome-wide
methodologies. The onset of translatome profiling will change
this trend and important mechanistic data will surface in the
coming years (Ingolia et al., 2009, 2018). Thirty-nine years after
its discovery, eIF4E still poses an enigma as to the identity of
the mRNAs it controls and the precise regulatory mechanisms
it participates in during different stages of development and in
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different cell-types of the brain. Understanding the role of cap-
dependent translation in the brain will facilitate the adaptation
of the already existing compendium of biochemical/genetic
models and pharmacological approaches to modulate translation
(Sonenberg and Hinnebusch, 2007; Malina et al., 2011, 2012), for
the treatment of neuropsychiatric disorders.
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